The genotype distributions of MT2A (rs28366003) SNP in prostate cancer and breast cancer described by Krześlak et al. [20, 21] confirm those given in the present study and were found to be A/A in 76 %, A/G in 21.1 %, G/G in 2.9 % and A/A in 87.1 %, A/G in 12.3 %, G/G in 0.6 % in prostate and breast cancer cases, respectively. Here, MT2A is linked to breast carcinoma.